Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study

References

• Srisurapanont M, , Maneeton BManeeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004;2:DOI 10.1002/14651858.CD000967.pub2.
   Google Scholar
• Hatim A, Habil H, Jesjeet SG, et al. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania. Hum Psychopharmacol 2006; 21: 313–8
   PubMed Web of Science ®Google Scholar
• Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Exp Opin Pharmacother 2006; 7: 929–40
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23: 1839–54
   PubMed Web of Science ®Google Scholar
• Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 2004; 20: 44–7
   PubMed Web of Science ®Google Scholar
• Hirscheld RMA, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I and II depression: A secondary analysis from a randomised double-blind placebo-controlled study. J Clin Psychiatry 2006; 67: 355–362
   PubMed Web of Science ®Google Scholar
• Chengappa KNR, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25: 530–41
   PubMed Web of Science ®Google Scholar
• Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005; 20: 237–41
   PubMed Web of Science ®Google Scholar
• Remington G. Rational pharmacotherapy in early psychosis. Br J Psychiatry 2005; 187(Suppl 48)77–84
   Google Scholar
• Tauscher-Wisnieski S, Kapur S, Tauscher J, et al. Quetiapine: An effective antipsychotic in first episode schizophrenia despite only transient high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 63: 992–7
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling HJ, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews 2003;4: DOI 10.1002/14651858.CD004410.
   Google Scholar
• Feetam C, Donoghue J. Antipsychotics in the treatment of first-episode schizophrenia. Pharm J 2003; 270: 405–8
   Google Scholar
• Potvin S, Pamoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77: 796–798
   PubMed Web of Science ®Google Scholar
• Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000; 4: 41–6
   PubMed Web of Science ®Google Scholar
• Mladsi DM, Grogg AL, Irish WD, et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin 2004; 20: 1883–93
   PubMed Web of Science ®Google Scholar
• Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38: 206–13
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J, Lindenmayer J-P. Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. J Clin Psychiatry 2005; 66: 1512–16
   PubMed Web of Science ®Google Scholar
• Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14: 372–94
   PubMed Web of Science ®Google Scholar
• International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry 2005;187(Suppl. 48):s120–4.
   Web of Science ®Google Scholar
• Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85: 254–65
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep 1962; 10: 799–912
   Web of Science ®Google Scholar
• Kay S. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
   PubMed Web of Science ®Google Scholar
• Schutte NS, Malouff JM. Measures of global functioning. Sourcebook of adult assessment strategies, NS Schutte, JM Malouff. Plenum Press, New York 1995; 461
   Google Scholar
• Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970; 212(Suppl 44)11–9
   Google Scholar
• Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6
   PubMed Web of Science ®Google Scholar
• Guy W. In: ECDEU Assessment Manual for Psychopharmacology, revised edition. Washington, DC, US Department of Health Education and Welfare. Publication (ADM) 76–338; 1976. p 534.
   Google Scholar
• Kopola LC, Good KP, Milliken H, et al. Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes. Schizophr Res 2006; 81: 29–39
   PubMed Web of Science ®Google Scholar
• O'Toole M, Taylor T, Walters J, Ohson R, Purvis L, Pilowsky. The Southwark First Onset Psychosis Service (FIRST): A longitudinal prospective follow-up study of quetiapine treatment in first-episode schizophrenia. Schizophr Res 2003;60((Suppl)):327.
   Google Scholar
• Stigler K, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents. Pediatr Drugs 2004; 6: 33–44
   PubMedGoogle Scholar
• Larsen TK, Melle I, Auestad B, et al. Substance abuse in first-episode non-affective psychosis. Schizophr Res 2006; 88: 55–62
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins D, Hamer RM. Comparison of Atypicals in First-Episode psychosis (CAFE): A randomised 52-week comparison of olanzapine, quetiapine, and risperidone. Neuropsychopharmacol 2005; 30(Suppl): s201
   Web of Science ®Google Scholar
• Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063–5
   PubMed Web of Science ®Google Scholar
• Gasquet I, Haro JM, Novick D, et al. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int J Clin Psychopharmacol 2005; 20: 199–205
   PubMed Web of Science ®Google Scholar
• Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can J Psychiatry 2003; 48: 272–6
   PubMed Web of Science ®Google Scholar
• Catts SV, Carr VJ, O'Toole BI, et al. Variance components model predicting outcome in a multi-site multi-level study of early psychosis treatment. Schizophr Bull. 2007; 33: 584–5
   Web of Science ®Google Scholar